Intravitreous tap and injection of vancomycin hydrochloride, 1 mg, ceftazidime, 2.25 mg, and dexamethasone sodium phosphate, 0.4 mg, was performed on the day of the initial visit, and broad-spectrum treatment with intravenous vancomycin and ceftazidime was started (Figure, A). Within 12 hours, the vitreous culture was positive for Salmonella serotype B sensitive to fluoroquinolones, aminoglycosides, cephalosporins, trimethoprim sulfate, ampicillin, and meropenem. Because visual acuity remained at light perception and the clinical signs were not improving, pars plana vitrectomy and lensectomy were performed on the second posttreatment day. Intraoperatively, multiple peripheral retinal tears and sclerotic retinal vessels were noted. Two additional intravitreous injections of amikacin sulfate and ceftazidime were administered during follow-up. The extensive systemic workup ruled out an immunocompromised state. Blood culture results were negative. Stool culture was positive for Salmonella serotype B. Echocardiography, abdominal ultrasonography, chest radiography, computed tomography of the brain, computed tomography of the abdomen and pelvis, and an upper gastrointestinal tract series with a small-bowel series failed to identify any additional foci of infection. The patient received intravenous meropenem for 6 weeks. At the 4-month follow-up, visual acuity was no light perception and ocular hypotony was observed (Figure, B).